New options for combination therapy for advanced non-squamous NSCLC

Antonio Rossi

Research output: Contribution to journalReview article

Abstract

Introduction: Nonsquamous non-small-cell lung cancer (NSCLC) is divided in oncogene-addicted subgroups, highly expressed programmed death ligand-1 (PD-L1 ≥ 50%) subgroup, and ‘negative’ subgroup. The latter represents the most common group comprising about 50% of all new diagnoses of nonsquamous NSCLC. For this group, chemotherapy was the standard approach with pemetrexed- and/or bevacizumab-based regimens reaching an overall survival of about 12–17 months. Areas covered: This review will focus on the new options for combination therapies, which have already recently arrived or are going to arrive in the clinical practice, mainly through registrative trials, for the management of advanced nonsquamous non oncogene-addicted NSCLC. A structured search of bibliographic databases for peer-reviewed research literature and of main meetings using a focused review question was undertaken in order to discuss this topic. Expert opinion: In the ‘negative’ nonsquamous NSCLC patients, first-line combinations of pembrolizumab, an anti-PD-1, or atezolizumab, an anti-PD-L1, plus chemotherapy are already available in the clinical practice, regardless of PD-L1 expression. In this group of patients, the combinations of antiangiogenic agents, such as ramucirumab and nintedanib, in combination with docetaxel, become new options for second-line treatment. More studies are needed to investigate new combinations for the treatment of these patients.

Original languageEnglish
Pages (from-to)1095-1107
Number of pages13
JournalExpert Review of Respiratory Medicine
Volume13
Issue number11
DOIs
Publication statusPublished - Nov 2 2019

Fingerprint

Non-Small Cell Lung Carcinoma
docetaxel
Oncogenes
Pemetrexed
Bibliographic Databases
Drug Therapy
Angiogenesis Inhibitors
Expert Testimony
Therapeutics
Ligands
Survival
Research

Keywords

  • Antiangiogenic
  • checkpoint inhibitors
  • immunotherapy
  • nintedanib
  • nonsquamous
  • NSCLC
  • ramucirumab
  • regimen
  • resistance

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine
  • Public Health, Environmental and Occupational Health

Cite this

New options for combination therapy for advanced non-squamous NSCLC. / Rossi, Antonio.

In: Expert Review of Respiratory Medicine, Vol. 13, No. 11, 02.11.2019, p. 1095-1107.

Research output: Contribution to journalReview article

@article{00ba551f88fd4f9289d54d2c3386d624,
title = "New options for combination therapy for advanced non-squamous NSCLC",
abstract = "Introduction: Nonsquamous non-small-cell lung cancer (NSCLC) is divided in oncogene-addicted subgroups, highly expressed programmed death ligand-1 (PD-L1 ≥ 50{\%}) subgroup, and ‘negative’ subgroup. The latter represents the most common group comprising about 50{\%} of all new diagnoses of nonsquamous NSCLC. For this group, chemotherapy was the standard approach with pemetrexed- and/or bevacizumab-based regimens reaching an overall survival of about 12–17 months. Areas covered: This review will focus on the new options for combination therapies, which have already recently arrived or are going to arrive in the clinical practice, mainly through registrative trials, for the management of advanced nonsquamous non oncogene-addicted NSCLC. A structured search of bibliographic databases for peer-reviewed research literature and of main meetings using a focused review question was undertaken in order to discuss this topic. Expert opinion: In the ‘negative’ nonsquamous NSCLC patients, first-line combinations of pembrolizumab, an anti-PD-1, or atezolizumab, an anti-PD-L1, plus chemotherapy are already available in the clinical practice, regardless of PD-L1 expression. In this group of patients, the combinations of antiangiogenic agents, such as ramucirumab and nintedanib, in combination with docetaxel, become new options for second-line treatment. More studies are needed to investigate new combinations for the treatment of these patients.",
keywords = "Antiangiogenic, checkpoint inhibitors, immunotherapy, nintedanib, nonsquamous, NSCLC, ramucirumab, regimen, resistance",
author = "Antonio Rossi",
year = "2019",
month = "11",
day = "2",
doi = "10.1080/17476348.2019.1667233",
language = "English",
volume = "13",
pages = "1095--1107",
journal = "Expert Review of Respiratory Medicine",
issn = "1747-6348",
publisher = "Expert Reviews Ltd.",
number = "11",

}

TY - JOUR

T1 - New options for combination therapy for advanced non-squamous NSCLC

AU - Rossi, Antonio

PY - 2019/11/2

Y1 - 2019/11/2

N2 - Introduction: Nonsquamous non-small-cell lung cancer (NSCLC) is divided in oncogene-addicted subgroups, highly expressed programmed death ligand-1 (PD-L1 ≥ 50%) subgroup, and ‘negative’ subgroup. The latter represents the most common group comprising about 50% of all new diagnoses of nonsquamous NSCLC. For this group, chemotherapy was the standard approach with pemetrexed- and/or bevacizumab-based regimens reaching an overall survival of about 12–17 months. Areas covered: This review will focus on the new options for combination therapies, which have already recently arrived or are going to arrive in the clinical practice, mainly through registrative trials, for the management of advanced nonsquamous non oncogene-addicted NSCLC. A structured search of bibliographic databases for peer-reviewed research literature and of main meetings using a focused review question was undertaken in order to discuss this topic. Expert opinion: In the ‘negative’ nonsquamous NSCLC patients, first-line combinations of pembrolizumab, an anti-PD-1, or atezolizumab, an anti-PD-L1, plus chemotherapy are already available in the clinical practice, regardless of PD-L1 expression. In this group of patients, the combinations of antiangiogenic agents, such as ramucirumab and nintedanib, in combination with docetaxel, become new options for second-line treatment. More studies are needed to investigate new combinations for the treatment of these patients.

AB - Introduction: Nonsquamous non-small-cell lung cancer (NSCLC) is divided in oncogene-addicted subgroups, highly expressed programmed death ligand-1 (PD-L1 ≥ 50%) subgroup, and ‘negative’ subgroup. The latter represents the most common group comprising about 50% of all new diagnoses of nonsquamous NSCLC. For this group, chemotherapy was the standard approach with pemetrexed- and/or bevacizumab-based regimens reaching an overall survival of about 12–17 months. Areas covered: This review will focus on the new options for combination therapies, which have already recently arrived or are going to arrive in the clinical practice, mainly through registrative trials, for the management of advanced nonsquamous non oncogene-addicted NSCLC. A structured search of bibliographic databases for peer-reviewed research literature and of main meetings using a focused review question was undertaken in order to discuss this topic. Expert opinion: In the ‘negative’ nonsquamous NSCLC patients, first-line combinations of pembrolizumab, an anti-PD-1, or atezolizumab, an anti-PD-L1, plus chemotherapy are already available in the clinical practice, regardless of PD-L1 expression. In this group of patients, the combinations of antiangiogenic agents, such as ramucirumab and nintedanib, in combination with docetaxel, become new options for second-line treatment. More studies are needed to investigate new combinations for the treatment of these patients.

KW - Antiangiogenic

KW - checkpoint inhibitors

KW - immunotherapy

KW - nintedanib

KW - nonsquamous

KW - NSCLC

KW - ramucirumab

KW - regimen

KW - resistance

UR - http://www.scopus.com/inward/record.url?scp=85073578914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073578914&partnerID=8YFLogxK

U2 - 10.1080/17476348.2019.1667233

DO - 10.1080/17476348.2019.1667233

M3 - Review article

C2 - 31512526

AN - SCOPUS:85073578914

VL - 13

SP - 1095

EP - 1107

JO - Expert Review of Respiratory Medicine

JF - Expert Review of Respiratory Medicine

SN - 1747-6348

IS - 11

ER -